Clinical trials: Sunitinib
Gastrointestinal Stromal Tumors, Surgery
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
This study evaluates the efficacy and safety of surgical intervention in patients with focally progressive GISTs after imatinib treatment.
- Trial name
- NCT03862768
- Testing
- surgery, Imatinib 400 MG, Imatinib escalation
- Volunteers
- 92 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Kidney Neoplasms, Carcinoma, Renal Cell
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to…
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Trial name
- NCT00537056
- Testing
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Gastrointestinal Neoplasm
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies…
- Trial name
- NCT00094029
- Testing
- Sutent
- Where
- 118 sites in United States, Argentina and 32 more
- Sponsor
- Pfizer
Unresectable and Advanced Cholangiocarcinoma
A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered as the reference treatment in first line chemotherapy.
- Trial name
- SUN-CK (NCT01718327)
- Testing
- Sunitinib
- Where
- 6 sites in France
- Volunteers
- 53 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their…
- Trial name
- NCT00555672
- Testing
- 5-fluorouracil, cisplatin, sunitinib malate
- Where
- 3 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Pfizer
Renal Cell Cancer
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
The rapid development of agents blocking kinases has established the use of molecularly targeted therapy as the preferred treatment approach for patients with metastatic renal cell cancer (RCC).
- Trial name
- NCT02071719
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- M. Labots
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00890747
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one…
- Trial name
- NCT00338884
- Testing
- Sunitinib malate
- Where
- 15 sites in Argentina, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Kidney Cancer, Biomarkers
Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas
Renal cell carcinoma accounts for 2-3% of all cancers in western countries. Brazilian kidney cancer data show an incidence of 6,270 new cases for 2018.
- Conditions
- Kidney Cancer, Biomarkers, Gene Expression
- Trial name
- NCT04415697
- Testing
- Gene expression test using nanostring technology.
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Barretos Cancer Hospital
Kidney Cancer, Renal Cell Carcinoma Metastatic
TDM for Optimized Outcome in Patients With mRCC.
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma Metastatic, Drug Toxicity, Drug Side Effect
- Trial name
- NCT04659343
- Testing
- Measurement of concentration of active metabolite in cancer treatment.
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Niels Fristrup
Renal Cell Carcinoma Metastatic
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, and maximal tolerated dose (MTD) of the combination of Abemaciclib and Sunitinib administered orally in patients with advanced and metastatic renal cell…
- Trial name
- NCT03905889
- Testing
- Abemaciclib, Sunitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Brown University
Metastatic Renal Cell Carcinoma
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
This is a retrospective, non-interventional study which looks at the cohort of Renal Cell Carcinoma patients in a real life clinical setting and analyses into factors why these patients have been surviving for as long as 3-5…
- Trial name
- NCT01917214
- Testing
- Sutent: Observational Study
- Volunteers
- 212 people
- Sponsor
- Pfizer
Clear Cell Metastatic Renal Cell Carcinoma
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Disease and Stage: naïve metastatic kidney cancer. A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
- Trial name
- BIONIKK (NCT02960906)
- Testing
- Nivolumab, Ipilimumab, Pazopanib
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Intraocular Melanoma
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00489944
- Testing
- cisplatin, sunitinib malate, tamoxifen citrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Renal Cell Carcinoma, Metastatic
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib…
- Trial name
- MERECA (NCT02432846)
- Testing
- Intuvax (INN: ilixadencel), Sunitinib
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 88 people
- Sponsor
- Mendus